 Shares of Actinium Pharmaceuticals Inc. ATNM, 24.20 were up 22.8 in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for relapsed or refractory acute myeloid leukemia. Actinium said it plans to share additional clinical data by the end of the year. 